Share This Page
Suppliers and packagers for DELESTROGEN
✉ Email this page to a colleague
DELESTROGEN
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Ph Health | DELESTROGEN | estradiol valerate | INJECTABLE;INJECTION | 009402 | NDA | ENDO USA, Inc. | 42023-110-01 | 5 mL in 1 VIAL, MULTI-DOSE (42023-110-01) | 2007-11-01 |
| Ph Health | DELESTROGEN | estradiol valerate | INJECTABLE;INJECTION | 009402 | NDA | ENDO USA, Inc. | 42023-111-01 | 5 mL in 1 VIAL, MULTI-DOSE (42023-111-01) | 2007-11-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: DELESTROGEN
Introduction
DeLestrogen, a synthetic hormone therapy primarily comprising estradiol, is widely prescribed for menopausal symptom management, hormone replacement therapy (HRT), and certain estrogen deficiency conditions. Its global market relies on a complex network of pharmaceutical suppliers, encompassing active pharmaceutical ingredient (API) manufacturers, finished-dose producers, and distribution channels. Understanding the supplier landscape for DeLestrogen is critical for stakeholders involved in procurement, regulatory compliance, and strategic planning within the pharmaceutical industry.
Overview of DeLestrogen
DeLestrogen typically refers to formulations containing estradiol, which mimics endogenous estrogen hormone activity. It is available in various delivery forms, including oral tablets, patches, gels, and injections. The production of such a hormone necessitates high-purity APIs manufactured under stringent quality standards and then formulated into medicinal products by licensed pharmaceutical companies.
Key API Suppliers for DeLestrogen
1. Bayer AG
Bayer is a major player in hormonal APIs, including estradiol. Its established manufacturing facilities in Germany and the United States produce high-quality estradiol APIs following Good Manufacturing Practice (GMP) standards. Bayer's reputation for quality and reliability makes it a preferred supplier for pharmaceutical companies worldwide.
2. Pfizer Inc.
Pfizer is another significant API producer for estrogen compounds. Its global manufacturing footprint ensures a steady supply of estradiol APIs, frequently supplied to generic and branded drug manufacturers. Pfizer's APIs are known for their purity and compliance with international regulatory standards.
3. Sanofi
Sanofi manufactures estradiol APIs primarily through its European facilities, catering to both domestic and international markets. The company emphasizes innovation in hormone therapies, and its APIs are widely used in various contraceptive and menopausal products.
4. Novartis AG
Novartis produces estradiol APIs through its global R&D and manufacturing centers. The company’s focus on quality control and regulatory adherence makes it a reliable source for licensed hormone APIs, including those used in DeLestrogen formulations.
5. Sun Pharma
As one of India's leading generics manufacturers, Sun Pharma supplies estradiol APIs to both domestic and international markets. Their cost-effective production capabilities provide a competitive edge, especially in emerging markets.
6. LG Life Sciences / LG Chem
South Korean companies like LG Life Sciences and LG Chem have expanded their hormone API portfolios, including estradiol, supplying Asian markets and increasingly global markets as part of their strategic diversification.
Formulation and Finished-Product Manufacturers
Once APIs are procured, production shifts to pharmaceutical formulators specializing in menopausal hormone therapy products, including generic and branded versions of DeLestrogen.
1. Pfizer
Pfizer not only produces APIs but also formulates and markets FDA-approved estrogen-based therapies, securing vertical integration and supply chain control.
2. Novo Nordisk
Primarily known for insulin products, Novo Nordisk also develops hormone therapies and collaborates with API suppliers for estrogen formulations.
3. Mylan / Viatris
Mylan, now part of Viatris, produces various hormone replacement therapies, sourcing APIs from reputable suppliers to ensure product consistency and regulatory compliance.
4. Teva Pharmaceuticals
A leading generics manufacturer, Teva sources estrogen APIs from global API suppliers and develops DeLestrogen products for multiple markets.
Global Distribution and Supply Chain Considerations
The supply chain for DeLestrogen involves several critical factors:
-
Regulatory Compliance: Suppliers must adhere to GMP standards established by agencies such as the FDA (U.S.), EMA (Europe), and PMDA (Japan).
-
Quality Assurance: High purity and precise dosing are mandatory. Suppliers often undergo rigorous audits before qualifying as API providers.
-
Market Dynamics: Patent expirations have increased generic competition, affecting supplier pricing and availability.
-
Supply Chain Disruptions: Geopolitical issues, pandemics, and raw material shortages can substantially impact API availability.
Emerging Trends and Challenges
1. Biosimilar and Generic Competition
The expiration of patents for many estrogen products has led to a proliferation of biosimilars and generics, intensifying competition among suppliers. This creates opportunities for new entrants with competitive pricing but also necessitates compliance with evolving regulatory standards.
2. Quality and Regulatory Stringency
Global regulators are increasingly emphasizing stringent controls over API source quality. Suppliers must invest in technological upgrades to meet these standards, which can influence supplier selection.
3. Supply Chain Diversification
Pharmaceutical companies are diversifying their supplier base to mitigate risks associated with over-reliance on a limited number of API manufacturers, especially those concentrated in specific regions like China and India.
Conclusion
The supply landscape for DeLestrogen relies on a broad network of reputable API manufacturers, predominantly located in Europe, North America, and Asia. Major industry players such as Bayer, Pfizer, Sanofi, and Novartis maintain significant roles due to their capacity for high-quality production and regulatory compliance. Emerging market manufacturers like Sun Pharma and LG Chem are gaining prominence through cost-effective production and strategic expansion.
Strategic supplier selection hinges on quality assurance, regulatory adherence, cost efficiency, and supply chain resilience. As the market evolves amid patent expirations and regulatory tightening, pharmaceutical firms must continuously monitor supplier performance and diversify their sourcing channels to secure a stable supply of high-quality DeLestrogen products.
Key Takeaways
-
Major API Suppliers: Bayer, Pfizer, Sanofi, Novartis, and Sun Pharma are leading sources of estradiol APIs globally.
-
Quality and Compliance: Choosing suppliers with stringent GMP adherence and robust regulatory records is paramount.
-
Market Trends: Patent expirations have increased generic competition, influencing supplier selection and pricing strategies.
-
Supply Chain Risks: Diversification and proactive risk management are essential to mitigate disruptions.
-
Emerging Markets: Asian companies, notably Sun Pharma and LG Chem, are expanding their roles in hormone API supply, driven by cost advantages.
FAQs
1. Who are the leading global suppliers of estradiol APIs for DeLestrogen?
Major global API suppliers include Bayer, Pfizer, Sanofi, Novartis, and Sun Pharma, each recognized for high-quality estrogen APIs adhering to international regulatory standards.
2. How does regulatory compliance influence API supplier selection?
Regulatory compliance ensures that APIs meet safety, purity, and efficacy standards, which is vital for approval in target markets. Non-compliance risks regulatory rejection and product recalls.
3. Are there regional differences in API suppliers for DeLestrogen?
Yes. European and North American companies tend to focus on high-quality manufacturing, while Asian suppliers offer cost advantages and increased capacity, especially from India and South Korea.
4. How is supply chain resilience affecting DeLestrogen production?
Supply chain disruptions prompt companies to diversify suppliers, build inventory buffers, and engage with multiple manufacturing sites to secure consistent supply.
5. What are the future trends influencing DeLestrogen API suppliers?
The rise of biosimilars, stricter regulatory standards, patent expirations, and regional market expansion are shaping the supplier landscape, emphasizing quality, compliance, and diversification.
Sources
[1] European Medicines Agency. "Guideline on the quality of hormone replacement therapy." EMA, 2021.
[2] U.S. Food and Drug Administration. "Estrogen Products – Drug Approvals & Labeling." FDA, 2022.
[3] MarketWatch. "Global Hormone Replacement Therapy Market Analysis," 2023.
[4] IQVIA. "Global API Market Trends," 2022.
[5] Pharmaceutical Technology. "API manufacturing trends and challenges," 2022.
More… ↓
